KURA

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Wednesday, June 14, 2023
Exercise, Attention, Telephone, Jefferies, Cancer, BofA Securities, Sale, 3rd Floor, Prospectus, Jefferies Group, State Street, SVB, SAN, KURA, Form, Madison Avenue, Security (finance), SVB Securities

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

Key Points: 
  • SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
  • Kura is selling 5,660,871 shares of its common stock and pre-funded warrants to purchase 3,034,782 shares of its common stock in the offering.
  • The shares of common stock are being sold at a price to the public of $11.50 per share, and the pre-funded warrants are being sold at a price to the public of $11.4999 per pre-funded warrant.
  • In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,304,347 shares of common stock.

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Tuesday, June 13, 2023
Attention, Telephone, Jefferies, Cancer, BofA Securities, Sale, 3rd Floor, Prospectus, Jefferies Group, State Street, SVB, SAN, KURA, Form, Madison Avenue, Security (finance), SVB Securities

In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the securities offered in the public offering.

Key Points: 
  • In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the securities offered in the public offering.
  • All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be offered by Kura.
  • There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • BofA Securities, Jefferies and SVB Securities are acting as joint bookrunning managers in the offering.

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Sunday, June 11, 2023
Postcholecystectomy syndrome, Menin, Continuity, Venetoclax, Crystal structure, Cancer, Mutation, Massachusetts General Hospital, Kura, MEN1, Acute myeloid leukemia, Congress, Mixed-phenotype acute leukemia, AML, Dor, Patient, KURA, EHA, IDH, FLT3, SCT, CRi, Hospital, Poster, Safety, Disease, Pharmaceutical industry

The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.

Key Points: 
  • The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.
  • Notably, 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib.
  • Two patients underwent a stem cell transplant (SCT) and remain in remission as of the data cutoff, including one on post-SCT ziftomenib maintenance therapy.
  • “The clinical data presented today continue to demonstrate the ability of ziftomenib to drive durable responses as a monotherapy in heavily pretreated patients with NPM1-mutant AML.

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Tuesday, May 30, 2023
Abstract, Congress, Cancer, AML, SAN, KURA, EHA, Pharmaceutical industry

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.

Key Points: 
  • ET on Monday, June 12, 2023 –
    SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company’s menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.
  • Late-breaking abstract # LB2713, entitled “Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory NPM1-mutated AML,” will be presented at the late-breaking oral session from 9:45-11:15 CET on Sunday, June 11, 2023.
  • Late-breaking abstracts are scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023.
  • The event will be webcast live and can be accessed on the Investors section of Kura’s website at www.kuraoncology.com .

Kura Oncology to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 23, 2023
Cancer, Jefferies, Conference, SAN, KURA, Pharmaceutical industry, Communications satellite

SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Key Points: 
  • SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:
    A fireside chat at the virtual TD Cowen 4th Annual Oncology Innovation Summit at 1:30 p.m.
  • ET / 10:30 a.m. PT on May 30, 2023; and
    A fireside chat at the Jefferies Healthcare Conference in New York at 3:00 p.m.
  • ET / 12:00 p.m. PT on June 7, 2023.
  • Live audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com , with archived replays available following the events.

Kura Oncology Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
KRAS, AACR, Postcholecystectomy syndrome, European Hematology Association, CRH, Cancer, Lung cancer, Kura, ID, FTI, PI3, Daunorubicin, Acute myeloid leukemia, Renal cell carcinoma, Congress, AML, Azacitidine, Dor, Investment, Patient, EGFR, KURA, EHA, CR, FLT3, Webcast, Research, Axitinib, FDA, Safety, IND, Disease, Video game, Pharmaceutical industry, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2023 were $25.2 million, compared to $20.9 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $11.4 million, compared to $11.9 million for the first quarter of 2022.
  • ET / 1:30 p.m. PT today, May 10, 2023, to discuss the financial results for the first quarter 2023 and to provide a corporate update.

Kura Oncology to Participate in JMP Securities Life Sciences Conference

Retrieved on: 
Tuesday, May 9, 2023
Cancer, Conference, SAN, KURA, Pharmaceutical industry, Broadcasting

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference in New York.

Key Points: 
  • SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference in New York.
  • Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 11:00 a.m.
  • ET / 8:00 a.m. PT on May 16, 2023.
  • A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com , with an archived replay following the event.

Kura Oncology to Report First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Webcast, Cancer, SAN, KURA, Pharmaceutical industry, Auction

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023.

Key Points: 
  • SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023.
  • Kura’s management will host a webcast and conference call at 4:30 p.m.
  • ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
  • The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers.

Kura Oncology to Participate in Stifel Targeted Oncology Days

Retrieved on: 
Tuesday, April 18, 2023
Cancer, SAN, KURA, Pharmaceutical industry, Broadcasting

SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2023 Targeted Oncology Days.

Key Points: 
  • SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2023 Targeted Oncology Days.
  • Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:00 p.m.
  • ET / 10:00 a.m. PT on April 25, 2023.
  • A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com , with an archived replay following the event.

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

Retrieved on: 
Monday, April 17, 2023
Immortalised cell line, TKI, AACR, RCC, Cancer, American Association for Cancer Research, Farnesol, NSCLC, Lung cancer, Kura, FTI, Patient, KURA, Axitinib, Safety, Pharmaceutical industry

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported preclinical data supporting the potential use of farnesyl transferase inhibitors (FTIs) to treat various types of solid tumors in combination with targeted therapies, including KRASG12C inhibitors and anti-angiogenic tyrosine kinase inhibitors (TKIs). These data were featured in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting on Sunday, April 16 in Orlando. Copies of the posters are available on Kura’s website at www.kuraoncology.com/pipeline/publications.

Key Points: 
  • These data were featured in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting on Sunday, April 16 in Orlando.
  • “Although targeted therapies have demonstrated meaningful clinical activity, including objective responses, across a range of solid tumors, over time adaptive resistance almost invariably emerges, limiting the ability of the targeted therapies to drive sustained clinical benefit.
  • Yesterday, we presented encouraging preclinical data that highlight the potential for FTIs to prevent or delay emergence of resistance to certain classes of targeted therapies,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • Following completion of the dose escalation as a monotherapy, Kura plans to evaluate KO-2806 in dose escalation combination cohorts in advanced solid tumors.